HYB:F:F-HOYA Corporation (EUR)

COMMON STOCK | Medical Instruments & Supplies |

Last Closing

USD 126.65

Change

0.00 (0.00)%

Market Cap

USD 44.70B

Volume

200.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

HOYA Corporation, a med-tech company, provides high-tech and medical products worldwide. It operates through three segments: Life Care, Telecommunication, and Other. The company offers life care products, including eyeglass and contact lenses; medical endoscopes; intraocular lenses; laparoscopic surgical instruments; automatic endoscope cleaning equipment; and other medical related products, such as prosthetic ceramic fillers and metallic implants for orthopedics. It also operates Eyecity, a specialty retailer of contact lenses. In addition, the company provides information technology products, such as mask blanks and photomasks for manufacturing semiconductor chips; glass disks for hard disk drives; and imaging products that include optical glasses/optical lenses, colored glass filters, and laser equipment/UV light resources. Further, it engages in the research, development, manufacture, and sale of photomasks for manufacturing flat panel displays. Additionally, the company offers ReadSpeaker, a speech synthesis software; and cloud services comprising Kinnosuke, a time and attendance management service, as well as Yonosuke, an electronic payslip service. HOYA Corporation was founded in 1941 and is headquartered in Tokyo, Japan.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-29 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
IUI1:F Intuitive Surgical Inc

N/A

USD 152.52B
ESL:F EssilorLuxottica Société ano..

N/A

USD 97.14B
ESLC:F ESSILORLUXOTTICA 1/2/O.N.

N/A

USD 96.96B
BOX:F Becton Dickinson and Company

N/A

USD 60.55B
HYB0:F HOYA CORP. ADR/ 1 O.N.

N/A

USD 43.06B
RMEA:F Resmed Inc DRC

N/A

USD 32.25B
RME:F ResMed Inc

N/A

USD 31.88B
CBH:F COLOPLAST SP.ADR 1/10 DK1

N/A

USD 26.54B
CBHD:F Coloplast A/S

N/A

USD 26.34B
QS50:F STRAUM.HLD.UNSP.ADR/1/10

N/A

USD 23.41B

ETFs Containing HYB:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -71.65% 6% D- 5% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -71.65% 6% D- 5% F
Trailing 12 Months  
Capital Gain -66.98% 9% A- 8% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return -66.98% 9% A- 8% B-
Trailing 5 Years  
Capital Gain -57.78% 27% F 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -57.78% 27% F 17% F
Average Annual (5 Year Horizon)  
Capital Gain 9.15% N/A N/A 68% D+
Dividend Return 9.15% N/A N/A 61% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 23.10% N/A N/A 57% F
Risk Adjusted Return 39.60% N/A N/A 62% D
Market Capitalization 44.70B 96% N/A 95% A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced on cashflow basis

The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector